Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing
- 3 September 2019
- journal article
- research article
- Published by Wiley in Journal of Genetic Counseling
- Vol. 28 (6), 1107-1118
- https://doi.org/10.1002/jgc4.1161
Abstract
Background Despite growing evidence of diagnostic yield and clinical utility of whole exome sequencing (WES) in patients with undiagnosed diseases, there remain significant cost and reimbursement barriers limiting access to such testing. The diagnostic yield and resulting clinical actions of WES for patients who previously faced insurance coverage barriers have not yet been explored. Methods We performed a retrospective descriptive analysis of clinical WES outcomes for patients facing insurance coverage barriers prior to clinical WES and who subsequently enrolled in the Undiagnosed Diseases Network (UDN). Clinical WES was completed as a result of participation in the UDN. Payer type, molecular diagnostic yield, and resulting clinical actions were evaluated. Results Sixty‐six patients in the UDN faced insurance coverage barriers to WES at the time of enrollment (67% public payer, 26% private payer). Forty‐two of 66 (64%) received insurance denial for clinician‐ordered WES, 19/66 (29%) had health insurance through a payer known not to cover WES, and 5/66 (8%) had previous payer denial of other genetic tests. Clinical WES results yielded a molecular diagnosis in 23 of 66 patients (35% [78% pediatric, 65% neurologic indication]). Molecular diagnosis resulted in clinical actions in 14 of 23 patients (61%). Conclusions These data demonstrate that a substantial proportion of patients who encountered insurance coverage barriers to WES had a clinically actionable molecular diagnosis, supporting the notion that WES has value as a covered benefit for patients who remain undiagnosed despite objective clinical findings.Keywords
This publication has 33 references indexed in Scilit:
- Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literatureGenetics in Medicine, 2018
- Diagnostic and cost utility of whole exome sequencing in peripheral neuropathyAnnals of Clinical and Translational Neurology, 2017
- Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providersGenetics in Medicine, 2017
- Health Care Infrastructure for Financially Sustainable Clinical GenomicsThe Journal of Molecular Diagnostics, 2016
- Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole‐exome sequencing as a first‐line diagnostic testClinical Genetics, 2016
- The Undiagnosed Diseases Network of the National Institutes of HealthJAMA, 2015
- Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 triosGenetics in Medicine, 2015
- Clinical Impact and Cost-Effectiveness of Whole Exome Sequencing as a Diagnostic Tool: A Pediatric Center’s ExperienceFrontiers in Pediatrics, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Chromosomal microarray impacts clinical managementClinical Genetics, 2013